FDA’s approval of alpelisib and fulvestrant in PIK3CA-mutated HR + /HER2− ABC, along with the updated ASCO guidelines, recognized PIK3CA mutation (tumor or liquid biopsy) as a biomarker to guide systemic therapy in ABC62,63. The gene discussed is PIK3CA; the disease is neoplasm.